ID   HD-MB03
AC   CVCL_S506
DR   DSMZ; ACC-740
DR   DSMZCellDive; ACC-740
DR   Wikidata; Q54882097
RX   PubMed=23054560;
RX   PubMed=27498314;
RX   PubMed=27812533;
CC   Doubling time: 23.32 hours (Note=Early passage), 23.98 hours (Note=Late passage) (PubMed=23054560); ~48 hours (DSMZ=ACC-740).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; None_reported; -; Zygosity=- (PubMed=23054560).
CC   Omics: Array-based CGH.
CC   Omics: Transcriptome analysis by microarray.
ST   Source(s): DSMZ=ACC-740
ST   Amelogenin: X,Y
ST   CSF1PO: 10,12
ST   D13S317: 11,12
ST   D16S539: 9,11
ST   D18S51: 12,13
ST   D19S433: 14,15
ST   D21S11: 30,31.2
ST   D2S1338: 24,27
ST   D3S1358: 14,15
ST   D5S818: 11
ST   D7S820: 9,10
ST   D8S1179: 12,14
ST   FGA: 21,22
ST   Penta D: 9,14
ST   Penta E: 5,15
ST   TH01: 6,9.3
ST   TPOX: 8,11
ST   vWA: 18,19
DI   NCIt; C129445; Medulloblastoma, non-WNT/non-SHH, group 3
DI   ORDO; Orphanet_616; Medulloblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   3Y
CA   Cancer cell line
DT   Created: 03-02-14; Last updated: 19-12-24; Version: 17
//
RX   PubMed=23054560; DOI=10.1007/s11060-012-0978-1;
RA   Milde T., Lodrini M., Savelyeva L., Korshunov A., Kool M.,
RA   Brueckner L.M., Antunes A.S.L.M., Oehme I., Pekrun A., Pfister S.M.,
RA   Kulozik A.E., Witt O., Deubzer H.E.;
RT   "HD-MB03 is a novel group 3 medulloblastoma model demonstrating
RT   sensitivity to histone deacetylase inhibitor treatment.";
RL   J. Neurooncol. 110:335-348(2012).
//
RX   PubMed=27498314; DOI=10.1016/j.jbiotec.2016.07.028;
RA   Ivanov D.P., Coyle B., Walker D.A., Grabowska A.M.;
RT   "In vitro models of medulloblastoma: choosing the right tool for the
RT   job.";
RL   J. Biotechnol. 236:10-25(2016).
//
RX   PubMed=27812533; DOI=10.1016/j.dib.2016.10.004; PMCID=PMC5079239;
RA   Ivanov D.P., Walker D.A., Coyle B., Grabowska A.M.;
RT   "Data on the number and frequency of scientific literature citations
RT   for established medulloblastoma cell lines.";
RL   Data Brief 9:696-698(2016).
//